Danaher (DHR) Stock Price Down 5.4% Following Insider Selling

Danaher Co. (NYSE:DHR)’s share price dropped 5.4% during mid-day trading on Monday following insider selling activity. The company traded as low as $96.29 and last traded at $96.70. Approximately 4,723,992 shares changed hands during mid-day trading, an increase of 76% from the average daily volume of 2,679,216 shares. The stock had previously closed at $102.18.

Specifically, SVP Angela S. Lalor sold 42,988 shares of the stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $102.29, for a total value of $4,397,242.52. Following the completion of the transaction, the senior vice president now owns 82,008 shares of the company’s stock, valued at $8,388,598.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Daniel L. Comas sold 62,989 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $101.96, for a total transaction of $6,422,358.44. Following the completion of the transaction, the chief financial officer now directly owns 227,805 shares of the company’s stock, valued at approximately $23,226,997.80. The disclosure for this sale can be found here. Insiders sold 274,913 shares of company stock valued at $27,729,293 in the last three months. Company insiders own 12.20% of the company’s stock.

DHR has been the subject of a number of research reports. Citigroup increased their target price on shares of Danaher to $107.00 and gave the stock a “buy” rating in a report on Friday, December 15th. Robert W. Baird reaffirmed a “buy” rating on shares of Danaher in a research note on Friday, January 12th. Royal Bank of Canada reaffirmed a “hold” rating and issued a $96.00 price objective on shares of Danaher in a research note on Thursday, January 4th. Stifel Nicolaus upped their price objective on Danaher from $110.00 to $115.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Finally, Credit Suisse Group upped their price objective on Danaher from $93.00 to $96.00 and gave the company an “outperform” rating in a research note on Friday, October 20th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. Danaher presently has an average rating of “Buy” and an average price target of $100.13.

The company has a market capitalization of $67,270.00, a PE ratio of 27.63, a price-to-earnings-growth ratio of 2.20 and a beta of 1.04. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.05 and a current ratio of 1.43.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.03. The business had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $4.97 billion. Danaher had a net margin of 13.60% and a return on equity of 11.36%. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.05 EPS. sell-side analysts anticipate that Danaher Co. will post 4.37 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, January 26th. Shareholders of record on Friday, December 29th were given a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a yield of 0.58%. The ex-dividend date was Thursday, December 28th. Danaher’s dividend payout ratio is presently 16.00%.

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in shares of Danaher by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 41,488,407 shares of the conglomerate’s stock worth $3,501,206,000 after buying an additional 520,776 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Danaher by 3.2% during the 2nd quarter. BlackRock Inc. now owns 39,201,798 shares of the conglomerate’s stock worth $3,308,239,000 after buying an additional 1,233,876 shares in the last quarter. FMR LLC boosted its holdings in shares of Danaher by 0.9% during the 2nd quarter. FMR LLC now owns 19,624,350 shares of the conglomerate’s stock worth $1,656,100,000 after buying an additional 183,183 shares in the last quarter. Parnassus Investments CA boosted its holdings in shares of Danaher by 0.3% during the 3rd quarter. Parnassus Investments CA now owns 9,796,584 shares of the conglomerate’s stock worth $840,351,000 after buying an additional 29,381 shares in the last quarter. Finally, Flossbach Von Storch AG boosted its holdings in shares of Danaher by 17.2% during the 3rd quarter. Flossbach Von Storch AG now owns 6,776,921 shares of the conglomerate’s stock worth $581,324,000 after buying an additional 994,902 shares in the last quarter. 76.19% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/05/danaher-dhr-stock-price-down-5-4-following-insider-selling.html.

About Danaher

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply